Sunney Li

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.

Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.

M. Provencio, J. Spicer, Shun Lu, 2020 .

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

J. Gainor, K. Ichikado, J. Sylvester, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.